Francesca Sacco

Dr. Francesca Sacco

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
FSFrancielli Santana
Francielli Santana
MPMAURO PERFETTI
MAURO PERFETTI
MBMatteo Briganti
Matteo Briganti
FSFrancesca Sacco
Francesca Sacco
Giordano PonetiGiordano Poneti
Giordano Poneti
RSRoberta Sessoli
Roberta Sessoli
A robust dysprosium(iii) single molecule magnet with large uniaxial magnetic anisotropy induces pseudocontact shifts at almost doubled distance compared to standard shift agents.

26 May 2022 in Journal of the American Chemical Society
Verified
Journal Article
Open access
DRDomenico Rizzo
Domenico Rizzo
LCLinda Cerofolini
Linda Cerofolini
SGStefano Giuntini
Stefano Giuntini
LILuisa Iozzino
Luisa Iozzino
CPCarlo Pergola
Carlo Pergola
MFMarco Fragai
Marco Fragai
Multispecific biologics are an emerging class of drugs, in which antibodies and/or proteins designed to bind pharmacological targets are covalently linked or expressed as fusion proteins to increase both therapeutic efficacy and safety. Epitope mapping on the target proteins provides key information to improve the affinity and also to monitor the manufacturing process and drug stability. Solid-state NMR has been here used to identify the pattern of the residues of the programmed cell death ligand 1 (PD-LI) ectodomain that are involved in the interaction with a new multispecific biological drug. This is possible because the large size and the intrinsic flexibility of the complexes are not limiting factors for solid-state NMR.

Verified
Journal Article
Open access
PDF file
FSFrancesca Sacco
Francesca Sacco
MTMatteo Tarchi
Matteo Tarchi
Giarita FerraroGiarita Ferraro
Giarita Ferraro
Antonello MerlinoAntonello Merlino
Antonello Merlino
Giorgio FacchettiGiorgio Facchetti
Giorgio Facchetti
LMLara Massai
Lara Massai
Three novel platinum(II) complexes bearing N-heterocyclic ligands, i.e., Pt2c, Pt-IV and Pt-VIII, were previously prepared and characterized. They manifested promising in vitro anticancer properties associated with non-conventional modes of action. To gain further mechanistic insight, we have explored here the reactions of these Pt compounds with a few model proteins, i.e., hen egg white lysozyme (HEWL), bovine pancreatic ribonuclease (RNase A), horse heart cytochrome c (Cyt-c) and human serum albumin (HSA), primarily through ESI MS analysis. Characteristic and variegate patterns of reactivity were highlighted in the various cases that appear to depend both on the nature of the Pt complex and of the interacting protein. The protein-bound Pt fragments were identified. In the case of the complex Pt2c, the adducts formed upon reaction with HEWL and RNase A were further characterized by solving the respective crystal structures: this allowed us to determine the exact location of the various Pt binding sites. The implications of the obtained results are discussed in relation to the possible mechanisms of action of these innovative anticancer Pt complexes.

22 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
FSFrancesca Sacco
Francesca Sacco
FBFabio Baroni
Fabio Baroni
ACAngela Capolupo
Angela Capolupo
SPSofia Petrocchi
Sofia Petrocchi
JZJonathan Zöller
Jonathan Zöller
MFMarco Fragai
Marco Fragai
Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.

22 August 2026 in Angewandte Chemie
Verified
Journal Article
Open access
FSFrancesca Sacco
Francesca Sacco
FBFabio Baroni
Fabio Baroni
ACAngela Capolupo
Angela Capolupo
SPSofia Petrocchi
Sofia Petrocchi
JZJonathan Zöller
Jonathan Zöller
MFMarco Fragai
Marco Fragai
Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.